AnaptysBio (ANAB) Metrics: History & Chart

AnaptysBio, Inc.(ANAB)

Biotechnology · San Diego, CA

$48.42-0.78 (-1.59%)

Delayed quote: Oct 6, 2026, 9:44 AM EDT

About AnaptysBio, Inc.

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

San Diego, CA

104 employees

www.anaptysbio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Daniel Faga

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-3.15%
30D Total Return	-13.38%
YTD Total Return	+52.23%
1Y Total Return	+138.49%
3Y Total Return	+273.87%
5Y Total Return	+165.18%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	+52.23%
2025	+266.02%
2024	-38.17%
2023	-30.88%
2022	-10.83%
2021	+61.69%
2020

CAGR TTM	+137.50%
CAGR 3Y	+55.19%
CAGR 5Y	+21.54%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	9.16
PE Ratio Avg TTM	9.41
PE Ratio Avg 3Y	9.41
Current VS TTM Avg	-2.64%
Current VS 3Y Avg	-2.64%
Current VS 5Y Avg	-86.66%

All Metrics

ANAB Valuation Metrics

ANAB Stock Price Metrics

ANAB Dividend Metrics

ANAB Growth Rate Metrics

ANAB Discounted Cash Flow Metrics

ANAB Returns By Period

ANAB Yearly Returns

ANAB Average Annual Returns By Period (CAGR)

ANAB Revenue Metrics

ANAB PE Ratio Metrics

ANAB PS Ratio Metrics

ANAB PB Ratio Metrics

ANAB Price to Free Cash Flow Ratio Metrics

ANAB Debt to Equity Ratio Metrics

ANAB PEG Ratio Metrics

ANAB FCF Yield

ANAB Earnings Yield

ANAB EBITDA Yield

ANAB OCF Yield

ANAB EV/EBIT Ratio Metrics

ANAB EV/EBITDA Ratio Metrics

ANAB EV/Assets Ratio Metrics

ANAB EV/Sales Ratio Metrics

ANAB Current Ratio Metrics

ANAB Quick Ratio Metrics

ANAB ROIC Metrics

ANAB Return on Assets Metrics

ANAB Return on Equity Metrics

ANAB Net Profit Margin Metrics

ANAB Gross Profit Margin Metrics

ANAB Tax Rate Metrics

PS Ratio	7.45
PS Ratio Avg TTM	6.28
PS Ratio Avg 3Y	11.75
Current VS TTM Avg	+18.65%
Current VS 3Y Avg	-36.59%
Current VS 5Y Avg	-46.85%

PB Ratio	167.21
PB Ratio Avg TTM	103.22
PB Ratio Avg 3Y	31.71
Current VS TTM Avg	+62.00%
Current VS 3Y Avg	+427.30%
Current VS 5Y Avg	+4355.98%

PFCF Ratio	98.14
PFCF Ratio Avg TTM	258.29
PFCF Ratio Avg 3Y	258.29
Current VS TTM Avg	-62.00%
Current VS 3Y Avg	-62.00%
Current VS 5Y Avg	-43.14%

Debt/Equity Ratio	25.47
Debt/Equity Ratio Avg TTM	8.58
Debt/Equity Ratio Avg 3Y	1.74
Current VS TTM Avg	+196.68%
Current VS 3Y Avg	+1363.41%
Current VS 5Y Avg	+24345.43%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	1.02%
FCF Yield Avg TTM	0.66%
FCF Yield Avg 3Y	0.66%
Current VS TTM Avg	+53.41%
Current VS 3Y Avg	+53.41%
Current VS 5Y Avg	-22.86%

Earnings Yield	10.91%
Earnings Yield Avg TTM	10.64%
Earnings Yield Avg 3Y	10.64%
Current VS TTM Avg	+2.55%
Current VS 3Y Avg	+2.55%
Current VS 5Y Avg	+646.46%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	14.23
Ev/Ebit Ratio Avg TTM	36.76
Ev/Ebit Ratio Avg 3Y	36.76
Current VS TTM Avg	-61.29%
Current VS 3Y Avg	-61.29%
Current VS 5Y Avg	-62.04%

Ev/Ebitda Ratio	14.04
Ev/Ebitda Ratio Avg TTM	34.83
Ev/Ebitda Ratio Avg 3Y	34.83
Current VS TTM Avg	-59.69%
Current VS 3Y Avg	-59.69%
Current VS 5Y Avg	-57.14%

Ev/Assets Ratio	6.01
Ev/Assets Ratio Avg TTM	4.11
Ev/Assets Ratio Avg 3Y	1.99
Current VS TTM Avg	+46.30%
Current VS 3Y Avg	+201.63%
Current VS 5Y Avg	+553.63%

Ev/Sales Ratio	8.02
Ev/Sales Ratio Avg TTM	6.77
Ev/Sales Ratio Avg 3Y	12.09
Current VS TTM Avg	+18.44%
Current VS 3Y Avg	-33.68%
Current VS 5Y Avg	-39.14%

Current Ratio	5.61
Current Ratio Avg TTM	7.83
Current Ratio Avg 3Y	9.24
Current VS TTM Avg	-28.33%
Current VS 3Y Avg	-39.23%
Current VS 5Y Avg	-56.38%

Quick Ratio	5.61
Quick Ratio Avg TTM	7.83
Quick Ratio Avg 3Y	9.24
Current VS TTM Avg	-28.33%
Current VS 3Y Avg	-39.23%
Current VS 5Y Avg	-56.38%

ROIC	47.55%
ROIC Avg 3Y	(23.52%)
ROIC Avg 5Y	(19.24%)
Current VS 3Y Avg	+302.20%
Current VS 5Y Avg	+347.21%
Current VS 10Y Avg	+381.02%

ROA	61.75%
ROA Avg TTM	9.67%
ROA Avg 3Y	(8.20%)
Current VS TTM Avg	+538.69%
Current VS 3Y Avg	+853.07%
Current VS 5Y Avg	+953.92%

ROE	1849.06%
ROE Avg TTM	(219.68%)
ROE Avg 3Y	(187.92%)
Current VS TTM Avg	+941.70%
Current VS 3Y Avg	+1083.97%
Current VS 5Y Avg	+1716.14%

Net Profit Margin	82.37%
Net Profit Margin Avg TTM	70.83%
Net Profit Margin Avg 3Y	(212.25%)
Current VS TTM Avg	+16.30%
Current VS 3Y Avg	+138.81%
Current VS 5Y Avg	+115.74%

Gross Profit Margin	98.97%
Gross Pft Margin Avg TTM	79.23%
Gross Pft Margin Avg 3Y	(60.24%)
Current VS TTM Avg	+24.91%
Current VS 3Y Avg	+264.30%
Current VS 5Y Avg	+130.72%

Tax Rate	(380.08%)
Tax Rate Avg 3Y	(126.64%)
Tax Rate Avg 5Y	(126.64%)
Current VS 3Y Avg	-200.13%
Current VS 5Y Avg	-200.13%
Current VS 10Y Avg	-400.21%